Vaccines have been a central focus for Trump's health leaders, but large-cap players aren't feeling the sting.

The company says its vaccine is on track for full approval, following delay. Novavax shares soared following the announcement.

Novavax said on Wednesday U.S. regulators asked the company to produce more data on its COVID-19 vaccine if it gets full ...

On a recent call with analysts at BMO Capital Markets, a “former director” at the FDA’s Center for Biologics Evaluation and ...

SK bioscience won a patent case against Moderna in Korea, impacting mRNA technology development and potential vaccine exports ...

SK bioscience Co., the biopharmaceutical arm of South Korea's SK Group, said Wednesday it has achieved a "final victory" in a ...

Moderna faces challenges with respiratory vaccine sales and strong competition. Click here to read an analysis of MRNA stock ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Advancements in mRNA vaccine technology are reshaping medicine, addressing challenges and expanding applications from ...

Furthering its goal to grow the reach of its mRNA vaccines and guard against future pandemics, Moderna cleared a key ...